{"id":2933,"date":"2006-10-07T10:50:24","date_gmt":"2006-10-07T09:50:24","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=2933"},"modified":"2013-12-06T16:01:55","modified_gmt":"2013-12-06T16:01:55","slug":"fixed-dose-combination-fdc-of-tenofovirftcefavirenz-atripla-filed-in-eu","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/2933","title":{"rendered":"Fixed dose combination (FDC) of tenofovir\/FTC\/efavirenz (Atripla) filed in EU"},"content":{"rendered":"<p><strong>On 9 October 2006, filing for the fixed-dose combination of tenofovir\/FTC\/efavirenz (Atripla) was submitted to the European regulatory authorities (Committee for Medicinal Products for Human Use (CHMP), subject to validation by the EMEA). It usually takes approximately 6 months from filing for the EMEA to approve a Marketing Authorisation Application, and for the drug to become commercially available.<\/strong><\/p>\n<p>This one-pill, once-daily formulation is the result of a collaboration between Gilead Sciences (manufacturers of tenofovir and FTC), Bristol-Myers Squibb, and Merck Sharp &amp; Dohme (who hold marketing rights for efavirenz in different European countries).<\/p>\n<p>The product contains 600 mg of efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, both nucleoside reverse transcriptase inhibitors (NRTIs).<\/p>\n<p>This FDC was approved in the US on 12 July 2006.<\/p>\n<p>Source: Gilead press release<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 9 October 2006, filing for the fixed-dose combination of tenofovir\/FTC\/efavirenz (Atripla) was submitted to the European regulatory authorities (Committee for Medicinal Products for Human Use (CHMP), subject to validation by the EMEA). It usually takes approximately 6 months from &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2933","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=2933"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2933\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=2933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=2933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=2933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}